Free Trial
NASDAQ:GNCA

Genocea Biosciences (GNCA) Stock Price, News & Analysis

Genocea Biosciences logo

About Genocea Biosciences Stock (NASDAQ:GNCA)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
83,499 shs
Market Capitalization
$6,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Remove Ads
Receive GNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

GNCA Stock News Headlines

Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
Genocea Biosciences Inc GNCAQ
The unusual signal flashing green again
Something fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.
GNCAQ Genocea Biosciences, Inc.
Genocea Biosciences, Inc. (GNCA)
GRPN, GNCA and LAB among mid-day movers
Genocea Biosciences to shut down
See More Headlines

GNCA Stock Analysis - Frequently Asked Questions

Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter.

Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW) and Micron Technology (MU).

Company Calendar

Last Earnings
10/27/2021
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNCA
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,200,000.00
Pretax Margin
-1,946.15%

Debt

Sales & Book Value

Annual Sales
$1.91 million
Price / Cash Flow
N/A
Book Value
$0.47 per share
Price / Book
N/A

Miscellaneous

Free Float
57,788,000
Market Cap
$6,000.00
Optionable
Not Optionable
Beta
1.61

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:GNCA) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners